FDA approves IMLYGIC™ developed by Biovex
The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application for IMLYGIC™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy for patients with a serious form of skin cancer. EU approval for IMLYGIC™ is expected during the next few months.
Biovex is a pioneering biotechnology company which created a new class of potent biologics for the treatment of cancer and prevention of infectious disease. Biovex was spun-out of UCL and acquired in January 2011 by US biotechnology giant Amgen Inc.